FinanceAsianet Newsable
Capricor stock rises ahead of FDA panel on Deramiocel
in5points
CAPR stock is on track for weekly gains ahead of an FDA advisory committee meeting.
The FDA advisory committee will review Capricor's application for Deramiocel on July 29.
Retail investors consider the upcoming FDA panel a 'binary event' for Capricor.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically